Additional European Equity News

Bayer (BAYN GY) - Co. and Cytokinetics (CYTK) announce exclusive licensing collaboration for Aficamten in Japan. Bayer is eligible to receive up to EUR 490mln in commericial milestone payments.  (Newswires) 

Diploma (DPLM LN) - FY (GBP): Revenue 1.36bln. Positive outlook for FY25. (Newswires) 

Endesa (ELE SM) - Says it is well on track to reach 2024 targets. For 2025: Sees EBITDA in range of EUR 5.4-5.6bln. 2024-27 dividend policy with 70% payout and guaranteed minimum dividend of EUR 1/shr. (Newswires) 

GSK (GSK LN) - Linerixibat shows positive Phase III results in cholestatic pruritus (relentless itch) in primary biliary cholangitis (PBC).  Primary endpoint met with a statistically significant improvement in itch over 24 weeks compared with placebo. (GSK)

Informa (INF LN) - Trading update: Revenue +10.7% Y/Y in first 10 months of 2024. Confirms double digit growth and reaffirms guidance. (Newswires) 

Imperial Brands (IMB LN) - FY (GBP): Op. Profit 3.55bln, +4.6% Y/Y, EPS 3.00 (exp. 2.88). Expects to deliver at least high-single-digit EPS growth at FY at constant currency. On track to deliver five year capital returns of GBP 10bln. Says performance will be weighted to second half of the year. Expects to deliver tobacco and NGP net rev. growth at low single digit constant currency. (Newswires)  

UBS (UBSG SW) - Co seeks expanded US banking license as it pushes for growth, according to Bloomberg. (Bloomberg)

19 Nov 2024 - 07:03- EquitiesExclusive- Source: Newsquawk